Therapeutic promise of dual blockade of IL-17 and TNF in inflammatory arthritis

Nature Reviews Rheumatology

Volumn 7, Issue 6, 2011, Pages 311-

  Buckland, Jenny ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

CALGRANULIN A; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 1; INTERLEUKIN 1 ANTIBODY; INTERLEUKIN 17; INTERLEUKIN 17 RECEPTOR; INTERLEUKIN 1BETA; MATRIX METALLOPROTEINASE; PROTEOGLYCAN; TUMOR NECROSIS FACTOR; TUMOR NECROSIS FACTOR ANTIBODY;

ARTHRITIS; BONE EROSION; CARTILAGE; CYTOKINE RESPONSE; DISEASE MODEL; DISEASE SEVERITY; DRUG POTENTIATION; EX VIVO STUDY; GENE EXPRESSION PROFILING; GENE OVEREXPRESSION; HUMAN; IMMUNOPATHOGENESIS; IN VIVO STUDY; JOINT BIOPSY; NONHUMAN; NOTE; PHARMACOLOGICAL BLOCKING; PRIORITY JOURNAL; PROTEIN DEPLETION; PROTEIN EXPRESSION; PROTEIN FUNCTION; TRANSCRIPTION INITIATION;

EID: 79958154418     PISSN: 17594790     EISSN: 17594804     Source Type: Journal    
DOI: 10.1038/nrrheum.2011.69     Document Type: Note

References (2)

1. Koenders, M. I. et al. TNF/IL-17 interplay induces S100A8, IL-1(3 and MMPs, and drives irreversible cartilage destruction in vivo: Rationale for combination treatment during arthritis. Arthritis Rheum. doi:10.1002/art.30418
2. van Vollenhoven R. F. Unresolved issues in biologic therapy for rheumatoid arthritis. Nat. Rev. Rheumatol., 7, 205-215(2011)